Resumen
La variabilidad en la asistencia a pacientes que tienen un síndrome coronario agudo se viene detectando desde hace más de 15 años en registros internacionales y nacionales. Dicha variabilidad depende de determinadas características de los pacientes, como el hecho de ser mujer o diabético, pero también de los centros y los médicos encargados de la asistencia. Se ha demostrado repetidamente la paradoja de tratar de forma menos completa o menos acorde con las guías cuanto mayor es el riesgo del paciente. Conocer todas las circunstancias que influyen en la variabilidad y aplicar medidas para minimizarlas, ayudará a mejorar el pronóstico de los pacientes.
Palabras clave
Síndrome coronario agudo
Tratamiento
Pronóstico
Abreviaturas
IGP
SCA
SCASEST
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
K.A. Fox, S.G. Goodman, W. Klein, D. Brieger, P.G. Steg, O. Dabbous, et al.
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).
Eur Heart J, (2002), 23 pp. 1177-1189
[2.]
A.F. Sonel, C.B. Good, J. Mulgund, M.T. Roe, W.B. Gibler, S.C. Smith Jr., et al.
Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?).
Circulation, (2005), 111 pp. 1225-1232
[3.]
D.L. Walters, C.N. Aroney, D.P. Chew, L. Bungey, S.G. Coverdale, R. Allan, et al.
Variations in the application of cardiac care in Australia. Results from a prospective audit of the treatment of patients presenting with chest pain.
MJA, (2008), 188 pp. 218-223
[4.]
M. Gulati, S. Patel, A.S. Jaffe, A.J. Joseph, J.E. Calvin.
Impact of contemporary guideline compliance on risk stratification models for acute coronary syndromes in the Registry of Acute Coronary Syndromes.
Am J Cardiol, (2004), 94 pp. 873-878
[5.]
K.A.A. Fox, F.A. Anderson, O.H. Dabbous, P.G. Steg, J. López-Sendón, F. Van de Werf, et al.
Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events GRACE.
Heart, (2007), 93 pp. 177-182
[6.]
A.T. Yan, R.T. Yan, M. Tan, A. Fung, A. Cohen, D.H. Fitchett, et al.
Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes.
Arch Intern Med, (2007), 167 pp. 1009-1016
[7.]
A.L. Blomkalns, A.Y. Chen, J.S. Hochman, E.D. Peterson, K. Trynosky, D. Diercks, et al.
Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Large-scale observations from the CRUSADE.
J Am Coll Cardiol, (2005), 45 pp. 832-837
[8.]
J. Alonso, H. Bueno, A. Bardají, X. García-Moll, X. Badia, M. Layola, et al.
Influencia del sexo en la mortalidad y el manejo del síndrome coronario agudo en España.
Rev Esp Cardiol Supl, (2008), 8 pp. 8D-22D
[9.]
J.-P. Bassand, C.W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernández-Avilés, et al.
Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST.
Rev Esp Cardiol, (2007), 60 pp. e1-e80
[10.]
H. Bueno.
Elección del tratamiento antitrombótico en pacientes con síndrome coronario agudo sin elevación del segmento ST de alto riesgo.
Rev Esp Cardiol Supl, (2005), 5 pp. 40C-46C
[11.]
The PURSUIT Trial Investigators.
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
N Engl J Med, (1998), 339 pp. 436-443
[12.]
E. Boersma, R.A. Harrington, D.J. Moliterno, H. White, P. Theroux, F. Van de Werf, et al.
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Lancet, (2002), 359 pp. 189-198
[13.]
R. Glaser, H.C. Herrmann, S.A. Murphy, L.A. Demopoulos, P.M. DiBattiste, C.P. Cannon, et al.
Benefit of an early invasive management strategy in women with acute coronary syndromes.
JAMA, (2002), 288 pp. 3124-3129
[14.]
C.P. Cannon, W.S. Weintraub, L.A. Demopoulos, R. Vicari, M.J. Frey, N. Lakkis, et al.
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
N Engl J Med, (2001), 344 pp. 1879-1887
[15.]
H. Bueno, A. Bardají, A. Fernández-Ortiz, J. Marrugat, H. Martí, M. Heras.
Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal ESpañol).
Rev Esp Cardiol, (2005), 58 pp. 244-252
[16.]
I. Ferreira-González, G. Permanyer-Miralda, J. Marrugat, M. Heras, J. Cuñat, E. Civeira, et al.
Estudio MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado). Resultados globales.
Rev Esp Cardiol, (2008), 61 pp. 803-816
[17.]
K. Franklin, R.J. Goldberg, F. Spencer, W. Klein, A. Budaj, D. Brieger, et al.
Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events.
Arch Intern Med, (2004), 164 pp. 1457-1463
[18.]
M. Roffi, D.P. Chew, D. Mukherjee, D.L. Bhatt, J.A. White, C. Heeschen, et al.
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
Circulation, (2001), 104 pp. 2767-2771
[19.]
T. Bauer, H. Möllmann, F. Weidinger, U. Zeymer, R. Seabra-Gomes, F. Eberli, et al.
Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.
Clin Res Cardiol, (2010), 99 pp. 375-383
[20.]
F. Arós, J. Marrugat, L. López-Bescos, A. Cabadés, A. Loma-Osorio, X. Bosch.
Accessibility to Coronary Angiography and One-Year Survival After Myocardial Infarction.
Am J Cardiol, (2002), 90 pp. 409-412
[21.]
J.M. Ruiz-Nodar, A. Cequier, T. Lozano, F. Fernández, I. Möller, S. Abán, et al.
Impacto del tipo de hospital en el tratamiento y evolución de los pacientes con síndrome coronario agudo sin elevación del ST.
Rev Esp Cardiol, (2010), 63 pp. 390-399
[22.]
I. Ferreira-González, G. Permanyer-Miralda, M. Heras, J. Cuñat, E. Civeira, F. Arós, et al.
Patterns of use and effectiveness of early invasive strategy in non–ST-segment elevation acute coronary syndromes: An assessment by propensity score.
Am Heart J, (2008), 156 pp. 946-953
[23.]
E.D. Peterson, Ch.V. Pollack, M.T. Roe, L.S. Parsons, K.A. Littrell, J.G. Canto, et al.
Early use of glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute myocardial infarction observations from the national registry of myocardial infarction 4.
J Am Coll Cardiol, (2003), 42 pp. 45-53
[24.]
P. Théroux, J. Alexander, J. Dupuis, Y. Pesant, P. Gervais, D. Grandmont.
Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management.
Am J Cardiol, (2001), 87 pp. 375-380
[25.]
O.H. Dabbous, F.A. Anderson, J.M. Gore, K.A. Eagle, K.A.A. Fox, R.H. Mehta.
Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary síndromes.
Heart, (2008), 94 pp. 159-165
[26.]
G. Bromberg-Marin, J.A. Marin-Neto, L.S. Parsons, J.C. Canto, W.J. Rogers.
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non–ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Am J Cardiol, (2006), 98 pp. 1125-1131
[27.]
B. Banihashemi, S.G. Goodman, R.T. Yan, R.C. Welsh, S.R. Mehta, G. Montalescot, et al.
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience.
Am Heart J, (2009), 158 pp. 917-924
[28.]
K.A. Eagle, C.K. Montoye, A.L. Riba, A.C. DeFranco, R. Parrish, S. Skorcz, et al.
Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction. The American College of Cardiology’s Guidelines Applied in Practice (GAP) Projects in Michigan.
J Am Coll Cardiol, (2005), 46 pp. 1242-1248
[29.]
E.D. Peterson, M.T. Roe, J. Mulgund, E.R. DeLong, B.L. Lytle, R.G. Brindis, et al.
Association between hospital process performance and outcomes among patients with acute coronary syndromes.
JAMA, (2006), 295 pp. 1912-1920
[30.]
M. Heras, H. Bueno, A. Bardají, A. Fernández-Ortiz, H. Martí, J. Marrugat.
Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES Registry.
Heart, (2006), 92 pp. 1571-1576
Copyright ©
2011. Sociedad Española de Cardiología